These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 22975610)

  • 1. Radiation therapy for neovascular age-related macular degeneration.
    Kishan AU; Modjtahedi BS; Morse LS; Lee P
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):583-97. PubMed ID: 22975610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy for neovascular age-related macular degeneration revisited.
    Kim IK; Gragoudas ES
    Br J Ophthalmol; 2009 Mar; 93(3):279-80. PubMed ID: 19244026
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation therapy: age-related macular degeneration.
    Mendez CA; Ehlers JP
    Dev Ophthalmol; 2013; 52():75-84. PubMed ID: 23989128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.
    Brown DM; Regillo CD
    Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
    Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
    Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Future methods of treatment in age related macular degeneration].
    Turlea C
    Oftalmologia; 2012; 56(1):30-5. PubMed ID: 22888684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
    Dugel PU; Petrarca R; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
    Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S; Rosenfeld PJ
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
    Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
    Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study].
    Baeteman C; Hoffart L; Galland F; Ridings B; Conrath J
    J Fr Ophtalmol; 2009 May; 32(5):309-13. PubMed ID: 19769866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidance for the treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM; Richard G; Augustin A; Aylward WG; Bandello F; Corcòstegui B; Cunha-Vaz J; Gaudric A; Leys A; Schlingemann RO;
    Acta Ophthalmol Scand; 2007 Aug; 85(5):486-94. PubMed ID: 17655610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting VEGF-A to treat cancer and age-related macular degeneration.
    Ferrara N; Mass RD; Campa C; Kim R
    Annu Rev Med; 2007; 58():491-504. PubMed ID: 17052163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
    Keane PA; Chang KT; Liakopoulos S; Jivrajka RV; Walsh AC; Sadda SR
    Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-macular degeneration agents.
    Rothen M; Jablon E; Monares G; Fontal MR; Alfaro DV
    Ophthalmol Clin North Am; 2005 Dec; 18(4):561-7. PubMed ID: 16314219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for age-related macular degeneration.
    Patel S
    Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of combination therapies for neovascular age-related macular degeneration.
    Couch SM; Bakri SJ
    Semin Ophthalmol; 2011 May; 26(3):114-20. PubMed ID: 21609223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.